Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H12ClN3O3S |
Molecular Weight | 289.739 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1NC(=O)C2=C(N1)C=C(Cl)C(=C2)S(N)(=O)=O
InChI
InChIKey=AGMMTXLNIQSRCG-UHFFFAOYSA-N
InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18600270Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19636250
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18600270
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19636250
Quinethazone (brand name Hydromox) is a thiazide diuretic used to treat hypertension. The antihypertensive mechanism of quinethazone is less well understood. This drug was discovered in a period when only isoform carbonic anhydrases (CAs) II was known and considered physiologically/pharmacologically relevant. Recently was studied that quinethazone considerably inhibit other isozymes known nowadays to be involved in critical physiologic processes. Thiazides like quinethazone also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. Common side effects include dizziness, dry mouth, nausea, and low potassium levels. Thiazides may increase the toxicity of allopurinol, anesthetics, antineoplastic, calcium salts, diazoxide, digitalis, lithium; loop diuretics, methyldopa, nondepolarizing muscle relaxants, vitamin D; amphotericin B and anticholinergics may increase the toxicity of thiazides.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095180 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18600270 |
|||
Target ID: CHEMBL1876 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20528637 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | HYDROMOX Approved UseUnknown Launch Date1963 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/quinethazone.html
50-100 mg once daily; usual maximum: 200 mg/day
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C03BA02
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
||
|
WHO-VATC |
QC03BB02
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
||
|
WHO-VATC |
QC03BA02
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
||
|
WHO-ATC |
C03BB02
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
||
|
NCI_THESAURUS |
C49185
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1532
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
DB01325
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
C66501
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
C050700
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
3392
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
8717
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
7289
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
998
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
DTXSID9023548
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
m9442
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
73-49-4
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
59743
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB10213MIG
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
6307
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
455E0S048W
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
100000080277
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
2343
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
759904
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
QUINETHAZONE
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY | |||
|
200-801-7
Created by
admin on Fri Dec 15 16:11:53 GMT 2023 , Edited by admin on Fri Dec 15 16:11:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY